Definium Therapeutics, Inc. 8-K

What Happened
Definium Therapeutics, Inc. (DFTX) announced in an 8-K filed June 12, 2026 that its shareholders approved an amendment to the company's 2025 Equity Incentive Plan to increase the number of common shares available for issuance by 5,000,000. The Board had previously approved the amendment on April 6, 2026, and the proposal was described in the company’s Definitive Proxy Statement filed April 27, 2026. The amendment became effective upon shareholder approval at the company’s 2026 Annual General and Special Meeting of Shareholders.

Key Details

• Share increase: 5,000,000 Common Shares added to the 2025 Equity Incentive Plan.
• Board approval: Amendment approved by the Board on April 6, 2026 (subject to shareholder approval).
• Proxy filing: Material terms summarized in the Definitive Proxy Statement on Schedule 14A filed April 27, 2026.
• 8-K filing and signature: Form 8-K filed June 12, 2026; signed by CEO Robert Barrow.

Why It Matters
Increasing the equity pool gives the company the capacity to grant additional stock-based awards (options, restricted stock, etc.) under its 2025 Equity Incentive Plan. For investors, that means Definium can use equity compensation for hiring, retention, or other corporate purposes; issuance of new awards would increase the total shares outstanding and could dilute existing shareholders. The filing documents the formal approval and timing, but does not disclose any specific upcoming grants or amounts to be awarded.